ProKidney Stock Soars Nearly 500% On Strong Phase 2 Results For CKD Therapy

(RTTNews) - ProKidney Corp. (PROK) shares surged 496.87 percent to $3.62 on Tuesday after the company announced positive topline results from its Phase 2 REGEN-007 trial evaluating rilparencel, a potential treatment for chronic kidney disease in patients with diabetes.

Shares opened at $1.27 and traded between $1.02 and $4.45 on the day, with volume spiking to 292.2 million shares, far above the 1.1 million average on the Nasdaq. The stock now trades near its 52-week high of $4.45, after closing at just $0.61 the previous session.

The therapy, which has FDA RMAT designation, showed statistically significant improvements in kidney function, bolstering confidence in its ongoing Phase 3 PROACT 1 trial. ProKidney plans to submit the full REGEN-007 data for presentation at the 2025 ASN Kidney Week and is preparing for an upcoming FDA Type B meeting regarding accelerated approval pathways.